61 patents
Utility
Use of Aminoquinoline Compounds for Higher Gene Integration
28 Dec 23
The invention provides aminoquinoline compounds as powerful enhancers of genetic recombination in living cells, especially to perform site-directed gene integration of exogenous DNA template by homologous recombination.
Alexandre JUILLERAT, Philippe DUCHATEAU, Ming YANG
Filed: 30 Nov 21
Utility
Cells for Immunotherapy Engineered for Targeting Antigen Present Both on Immune Cells and Pathological Cells
9 Nov 23
Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said immune cells (ex: CD38, CSI or CD70) by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute.
Philippe DUCHATEAU, Laurent POIROT
Filed: 22 May 23
Utility
Sequential Gene Editing In Primary Immune Cells
14 Sep 23
The invention pertains to the field of adaptive cell immunotherapy.
Jean-Pierre CABANIOLS, Jean-Charles EPINAT, Philippe DUCHATEAU
Filed: 19 Apr 23
Utility
Dual Car-t Cells
7 Sep 23
The present invention concerns new engineered immune cells expressing two CARs directed against two different targets, polynucleotides for preparing said immune cells, pharmaceutical compositions comprising said immune cells, and the use of said immune cells in the treatment of cancers.
André CHOULIKA, Laurent POIROT, Beatriz ARANDA ORGILLES, Philippe DUCHATEAU
Filed: 30 Jul 21
Utility
Methods to Genetically Modify Cells for Delivery of Therapeutic Proteins
7 Sep 23
The present disclosure provides methods to genetically modify cells by insertion of an artificial exon (ArtEx) for delivery of therapeutic proteins in specific cell types and more particularly engineered cells for expression of a transgene into the brain of a patient.
Alexandre JUILLERAT, Philippe DUCHATEAU, Patrick HONG, Laurent POIROT, Brian BUSSER, Alex BOYNE
Filed: 6 May 21
Utility
T-cells Expressing Immune Cell Engagers In Allogenic Settings
10 Aug 23
The invention relates to therapeutic compositions for allogeneic cellular therapy comprising TCR deficient T-cells, which are genetically engineered to express immune cell engagers, and methods related thereto.
Shipra DAS, Sumin JO, Alexandre JUILLERAT, Julien VALTON, Laurent POIROT, Philippe DUCHATEAU
Filed: 23 Jul 21
Utility
Method for determining potency of chimeric antigen receptor expressing immune cells
20 Jul 23
The invention relates to a new potency assay for characterizing the quality and activity of an immune cell expressing a chimeric antigen receptor, the kit to carry out this assay and uses thereof.
Xenia NAJ, Anne-Sophie Petit, Roman Galetto, Jean-Pierre Cabaniols
Filed: 2 Jul 21
Utility
Methods for Targeted Insertion of Exogenous Sequences In Cellular Genomes
6 Jul 23
The present disclosure provides methods for targeted insertion of an exogenous sequence at a genomic locus in a cell, wherein said insertion is induced by a sequence-specific endonuclease that has cleavage activity at said locus, at least 5 hours before the introduction into said cell of a DNA template comprising said exogenous sequence.
Ming YANG, Alexandre JUILLERAT, Philippe DUCHATEAU, Patrick HONG
Filed: 6 May 21
Utility
Methods for Engineering Allogeneic and Highly Active T Cell for Immunotheraphy
29 Jun 23
The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive.
Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cécile SCHIFFER-MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
Filed: 17 Nov 22
Utility
Combination Comprising Allogeneic Immune Cells Deficient for an Antigen Present on Both T-cells and Pathological Cells and Therapeutic Antibody Against Said Antigen
25 May 23
The present invention relates to a therapeutic combination of immune cells, preferably allogeneic non-alloreactive TCR-KO immune T cells, wherein a gene coding an antigen marker X present on both T-cells and pathological cells is inactivated and a corresponding therapeutic antibody specific for said antigen marker X, method for preparing the same and use in immunotherapy.
Philippe DUCHATEAU
Filed: 30 Jan 19
Utility
TAL- effector nuclease (TALEN) -MODIFIED ALLOGENIC CELLS SUITABLE FOR THERAPY
4 May 23
The invention relates to the fields of immunotherapy, molecular biology and recombinant nucleic acid technology.
Philippe DUCHATEAU, Brian BUSSER, Alexandre JUILLERAT, Anne-Sophie GAUTRON, Laurent POIROT
Filed: 19 Oct 17
Utility
Sequential Gene Editing In Primary Immune Cells
23 Mar 23
The invention pertains to the field of adaptive cell immunotherapy.
Jean-Pierre CABANIOLS, Jean-Charles EPINAT, Philippe DUCHATEAU
Filed: 5 Aug 22
Utility
New mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy
2 Mar 23
The present invention relates to engineered immune cells expressing new mesothelin (MLSN) specific chimeric antigen receptors (anti-mesothelin CAR) and their use in the treatment of solid tumors, particularly suited for allogeneic cell immunotherapy.
Cecile SCHIFFER-MANNIOUI, Philippe DUCHATEAU
Filed: 22 Dec 20
Utility
Methods for Engineering Highly Active T Cell for Immunotheraphy
23 Feb 23
The present invention relates to methods for developing engineered T-cells for immunotherapy and more specifically to methods for modifying T-cells by inactivating at immune checkpoint genes, preferably at least two selected from different pathways, to increase T-cell immune activity This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells.
Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cécile SCHIFFER-MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
Filed: 8 Apr 22
Utility
Methods for Engineering Allogeneic and Highly Active T Cell for Immunotheraphy
16 Feb 23
The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive.
Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cécile SCHIFFER-MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
Filed: 7 Apr 22
Utility
Use of Pre T Alpha or Functional Variant Thereof for Expanding TCR Alpha Deficient T Cells
3 Nov 22
A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex.
Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cecile MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
Filed: 24 Jun 22
Utility
Cellular Immunotherapy for Repetitive Administration
28 Jul 22
The present invention provides composition kits and methods for treating cancer in a human by immunotherapy using successive doses of CAR-T cells with no or reduced anamnestic immune reaction in one individual (P).
David SOURDIVE, Aymeric DUCLERT, Mathieu SIMON, Philippe DUCHATEAU, Alan Marc WILLIAMS, Laurent POIROT
Filed: 2 Jul 18
Utility
Use of Pre T Alpha or Functional Variant Thereof for Expanding TCR Alpha Deficient T Cells
9 Jun 22
A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex.
Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cecile MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
Filed: 17 Feb 22
Utility
Inhibitory Chimeric Antigen Receptors
3 Feb 22
ARVIND RAJPAL, Shobha Chowdary Potluri, Laurent Poirot, Alexandre Juillerat, Thomas Charles Pertel, Donna Marie Stone, Barbra Johnson Sasu
Filed: 26 Jul 21
Utility
Method for the Generation of Compact Tale-nucleases and Uses Thereof
13 Jan 22
The present invention relates to a method for the generation of compact Transcription Activator-Like Effector Nucleases (TALENs) that can efficiently target and process double-stranded DNA.
Philippe Duchateau, Julien Valton, Claudia Bertonati, Jean-Charles Epinat, George H. Silva, Alexandre Juillerat, Marine Beurdeley
Filed: 29 Sep 21